Dakota Wealth Management Sells 1,119 Shares of Danaher Co. (NYSE:DHR)

Dakota Wealth Management trimmed its position in Danaher Co. (NYSE:DHR) by 13.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 7,042 shares of the conglomerate’s stock after selling 1,119 shares during the quarter. Dakota Wealth Management’s holdings in Danaher were worth $1,616,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Decker Retirement Planning Inc. purchased a new position in Danaher during the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher during the third quarter valued at about $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher in the 3rd quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter worth approximately $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on DHR shares. Citigroup decreased their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research report on Friday, December 13th. UBS Group cut their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Finally, Robert W. Baird cut their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Stock Up 0.6 %

DHR opened at $245.73 on Friday. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a fifty day moving average of $234.90 and a two-hundred day moving average of $253.47. The stock has a market capitalization of $177.49 billion, a price-to-earnings ratio of 46.90, a PEG ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.02 earnings per share. On average, research analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.